IMV CEO Out After Six Years
HALIFAX—Frederic Ors has left his position as CEO of IMV Inc. The Halifax biopharmaceutical company announced Ors’ departure August 4.
In a news release, IMV board chair Andy Sheldon said Andrew Hall will take over as interim CEO while the board searches for a permanent replacement.
Hall has been with IMV, as its chief business officer, for approximately a year. He was formerly with Celgene and Merck.
Ors had been at the helm of IMV for approximately six years. During that time, the company established its proprietary DPX technology, an immunotherapy the company hopes will improve cancer treatment.
“[Ors’] vision, tenacity and leadership have been critical for building IMV’s story, and we wish him all the best in his future endeavours,” Sheldon said.
Sheldon added that, as IMV advances its technology, “the board determined that now is the right time to transition to new leadership.”
IMV’s share price has fallen by about 70 percent since it hit a high point in June 2020.
Last month, the company closed a US$25-million public offering.
Huddle could not reach Ors for comment. However, in a short social media statement, Ors said he was excited for the company’s future.
“Sad to be leaving but grateful for the opportunity I had to build a company with such a fantastic group of people. Go IMV Go! you have a bright future!” he wrote.